• English


Undergraduate Degree

  • Northwestern University , 1987 , Evanston , IL

Medical School

  • Northwestern University Medical School , 1989 , Chicago , IL


  • Children's Memorial Hospital , 1990 , Chicago , IL


  • Children's Memorial Hospital , 1992 , Chicago , IL


Pediatric Nephrology
  • Boston Children's Hospital , 1996 , Boston , MA


Michelle A. Baum, MD, is a member of Boston Children's Division of Nephrology. She specializes in treating children with spina bifida, kidney stones and other nephrological issues. Baum is an Assistant Professor of Medicine at Harvard Medical School.


  • American Board of Pediatrics, Pediatric Nephrology


Publications powered by Harvard Catalyst Profiles

  1. Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria. Kidney Int. 2021 Sep 02. View abstract
  2. Urodynamic characteristics of neurogenic bladder in newborns with myelomeningocele and refinement of the definition of bladder hostility: Findings from the UMPIRE multi-center study. J Pediatr Urol. 2021 Oct; 17(5):726-732. View abstract
  3. Pathophysiology and Treatment of Enteric Hyperoxaluria. Clin J Am Soc Nephrol. 2021 03 08; 16(3):487-495. View abstract
  4. Mutations of the Transcriptional Corepressor ZMYM2 Cause Syndromic Urinary Tract Malformations. Am J Hum Genet. 2020 10 01; 107(4):727-742. View abstract
  5. Pharmacological Dilutional Therapy Using the Vasopressin Antagonist Tolvaptan for Young Patients With Cystinuria: A Pilot Investigation. Urology. 2020 Oct; 144:65-70. View abstract
  6. Evaluation and Medical Management of Patients with Cystine Nephrolithiasis: A Consensus Statement. J Endourol. 2020 11; 34(11):1103-1110. View abstract
  7. Kidney Function Surveillance in the National Spina Bifida Patient Registry: A Retrospective Cohort Study. J Urol. 2020 09; 204(3):578-586. View abstract
  8. Urologic guidelines for the care and management of people with spina bifida. J Pediatr Rehabil Med. 2020; 13(4):479-489. View abstract
  9. Whole exome sequencing identified ATP6V1C2 as a novel candidate gene for recessive distal renal tubular acidosis. Kidney Int. 2020 03; 97(3):567-579. View abstract
  10. Whole-Exome Sequencing Enables a Precision Medicine Approach for Kidney Transplant Recipients. J Am Soc Nephrol. 2019 02; 30(2):201-215. View abstract
  11. Whole-Exome Sequencing Identifies Causative Mutations in Families with Congenital Anomalies of the Kidney and Urinary Tract. J Am Soc Nephrol. 2018 09; 29(9):2348-2361. View abstract
  12. Whole Exome Sequencing Reveals a Monogenic Cause of Disease in ˜43% of 35 Families With Midaortic Syndrome. Hypertension. 2018 04; 71(4):691-699. View abstract
  13. Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis. Kidney Int. 2018 01; 93(1):204-213. View abstract
  14. Analysis of 24 genes reveals a monogenic cause in 11.1% of cases with steroid-resistant nephrotic syndrome at a single center. Pediatr Nephrol. 2018 02; 33(2):305-314. View abstract
  15. Imaging in the diagnosis of pediatric urolithiasis. Pediatr Radiol. 2017 Jan; 47(1):5-16. View abstract
  16. Design and Methodological Considerations of the Centers for Disease Control and Prevention Urologic and Renal Protocol for the Newborn and Young Child with Spina Bifida. J Urol. 2016 12; 196(6):1728-1734. View abstract
  17. Mutations in SLC26A1 Cause Nephrolithiasis. Am J Hum Genet. 2016 06 02; 98(6):1228-1234. View abstract
  18. Prevalence of Monogenic Causes in Pediatric Patients with Nephrolithiasis or Nephrocalcinosis. Clin J Am Soc Nephrol. 2016 Apr 07; 11(4):664-72. View abstract
  19. Imaging and surgical utilization for pediatric cystinuria patients: A single-institution cohort study. J Pediatr Urol. 2016 Apr; 12(2):106.e1-7. View abstract
  20. Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. J Am Soc Nephrol. 2015 Mar; 26(3):543-51. View abstract
  21. Characteristics and survival of patients with end stage renal disease and spina bifida in the United States renal data system. J Urol. 2015 Feb; 193(2):558-64. View abstract
  22. Continuous renal replacement therapy for children =10 kg: a report from the prospective pediatric continuous renal replacement therapy registry. J Pediatr. 2013 Mar; 162(3):587-592.e3. View abstract
  23. Nonrenal indications for continuous renal replacement therapy: A report from the Prospective Pediatric Continuous Renal Replacement Therapy Registry Group. Pediatr Crit Care Med. 2012 Sep; 13(5):e299-304. View abstract
  24. Prenatal programming of rat cortical collecting tubule sodium transport. Am J Physiol Renal Physiol. 2012 Mar 15; 302(6):F674-8. View abstract
  25. Fluid overload and mortality in children receiving continuous renal replacement therapy: the prospective pediatric continuous renal replacement therapy registry. Am J Kidney Dis. 2010 Feb; 55(2):316-25. View abstract
  26. Protein and calorie prescription for children and young adults receiving continuous renal replacement therapy: a report from the Prospective Pediatric Continuous Renal Replacement Therapy Registry Group. Crit Care Med. 2008 Dec; 36(12):3239-45. View abstract
  27. Continuous renal replacement therapy (CRRT) after stem cell transplantation. A report from the prospective pediatric CRRT Registry Group. Pediatr Nephrol. 2008 Apr; 23(4):625-30. View abstract
  28. Demographic characteristics of pediatric continuous renal replacement therapy: a report of the prospective pediatric continuous renal replacement therapy registry. Clin J Am Soc Nephrol. 2007 Jul; 2(4):732-8. View abstract
  29. Outcome of renal transplantation for Wilms' tumor and Denys-Drash syndrome: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant. 2005 Jun; 9(3):305-10. View abstract
  30. Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT). Nephrol Dial Transplant. 2005 Jul; 20(7):1416-21. View abstract
  31. Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy. Kidney Int. 2005 Feb; 67(2):653-8. View abstract
  32. Outcomes after renal transplantation for FSGS in children. Pediatr Transplant. 2004 Aug; 8(4):329-33. View abstract
  33. Localization of Mg2+-sensing shark kidney calcium receptor SKCaR in kidney of spiny dogfish, Squalus acanthias. Am J Physiol Renal Physiol. 2003 Sep; 285(3):F430-9. View abstract
  34. Calpain-mediated AQP2 proteolysis in inner medullary collecting duct. Biochem Biophys Res Commun. 2003 Mar 28; 303(1):52-8. View abstract
  35. Outcome of renal transplantation in adolescents with focal segmental glomerulosclerosis. Pediatr Transplant. 2002 Dec; 6(6):488-92. View abstract
  36. AQP2 is a substrate for endogenous PP2B activity within an inner medullary AKAP-signaling complex. Am J Physiol Renal Physiol. 2001 Nov; 281(5):F958-65. View abstract
  37. Loss of living donor renal allograft survival advantage in children with focal segmental glomerulosclerosis. Kidney Int. 2001 Jan; 59(1):328-33. View abstract
  38. The role of the graft endothelium in transplant rejection: evidence that endothelial activation may serve as a clinical marker for the development of chronic rejection. Pediatr Transplant. 2000 Nov; 4(4):252-60. View abstract
  39. Recent insights into the coordinate regulation of body water and divalent mineral ion metabolism. Am J Med Sci. 1998 Nov; 316(5):321-8. View abstract
  40. The perinatal expression of aquaporin-2 and aquaporin-3 in developing kidney. Pediatr Res. 1998 Jun; 43(6):783-90. View abstract
  41. Vasopressin-elicited water and urea permeabilities are altered in IMCD in hypercalcemic rats. Am J Physiol. 1998 05; 274(5):F978-85. View abstract
  42. Renovascular hypertension in Marfan syndrome. Pediatr Nephrol. 1997 Aug; 11(4):499-501. View abstract